5 Key Takeaways

• 1

  The Access p-Tau217/β-Amyloid 1-42 plasma ratio test received Breakthrough Device Designation from the FDA.

• 2

  This blood test measures the ratio of phosphorylated tau protein and β-Amyloid 1-42 to detect Alzheimer's disease pathology.

• 3

  The test aims to provide a less invasive method for identifying amyloid pathology, a hallmark of Alzheimer's disease.

• 4

  It is designed to run on the DxI 9000 Immunoassay Analyzer platform using Lumi-Phos PRO substrate technology.

• 5

  The company plans to develop additional neurodegenerative disease diagnostics, though a market availability timeline is not disclosed.